Immunexpress is a molecular diagnostic company dedicated to enhancing outcomes for patients with suspected sepsis and healthcare providers. They are at the forefront of sepsis diagnosis, utilizing cutting-edge technology that analyzes the patient's immune system to rapidly detect sepsis. Unlike traditional approaches that focus on identifying the causative pathogen, Immunexpress' technology quantifies the patient's immune response to the pathogen using blood gene expression.

Their mission is to develop innovative diagnostic technologies that assist clinicians and patients in combatting this life-threatening disease. Sepsis, a medical emergency, is caused by an overwhelming immune response to an infection. If left undetected or untreated, it results in tissue damage, organ failure, permanent disability, and often death.

Immunexpress recognizes the challenges physicians face in swiftly and accurately identifying sepsis due to the absence of reliable diagnostic tools. To address this, they have developed the SeptiCyte® RAPID cartridge, a fully automated solution compatible with the Biocartis Idylla™ platform. This technology enables the quantification and analysis of gene expression from whole blood, allowing for the diagnosis of sepsis in suspected patients within one hour - a significant improvement compared to traditional tests.

Immunexpress aims to improve clinical and economic outcomes for patients and benefit healthcare stakeholders with their innovative technology, including medical professionals and payers. Through their focus on understanding the patient's immune response, they are revolutionizing sepsis diagnosis and contributing to the fight against this devastating disease